• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of March 1

Video

Here are the top 5 biosimilar articles for the week of March 1, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of March 1, 2021.

Number 5: During February, the rheumatology space saw several advancements in biosimilars, including 2 Canadian launches, an EU approval, and evidence to support the safety of nonmedical switching.

Number 4: Biocon and Viatris edge closer to EU marketing authorization for a bevacizumab biosimilar, among other biosimilar business developments.

Number 3: Sales of the pegfilgrastim oncology support biosimilar Udenyca fell off in late 2020, but Coherus doesn't see orginator company Amgen's advantage lasting much longer.

Number 2: A new set of guidelines for the use of biosimilars from the National Comprehensive Cancer Network (NCCN) addresses challenges of stocking biosimilars, dealing with procurement errors, and obtaining payer authorizations.

Number 1: Biosimilars have come a long way, and their path has mirrored that of generics—fraught with obstacles. Still, a stronger embrace is needed from physicians and payers.

To read all of these articles and more, visit centerforbiosimilars.com.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
The Top 5 Biosimilar Articles for the Week of August 4
Here are the top 5 biosimilar articles for the week of July 28, 2025.
Here are the top 5 biosimilar articles for the week of July 21, 2025.
© 2025 MJH Life Sciences

All rights reserved.